Methylphenidate

Narcolepsy, Attention Deficit Hyperactivity Disorder

Treatment

20 Active Studies for Methylphenidate

What is Methylphenidate

Methylphenidate

The Generic name of this drug

Treatment Summary

Methylphenidate is a medication used to treat Attention Deficit/Hyperactivity Disorder (ADHD) and narcolepsy. It is sold under the brand names Ritalin, Concerta, and Biphentin. Methylphenidate works by increasing the activity of certain brain chemicals, like dopamine and norepinephrine, which help to improve focus and attention. The effects of methylphenidate last up to 10-12 hours, so it can be taken once a day. However, methylphenidate has the potential to be abused and can cause addiction, so it is important to take it as prescribed by your doctor

Methylphenidate Hydrochloride

is the brand name

image of different drug pills on a surface

Methylphenidate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methylphenidate Hydrochloride

Methylphenidate

1955

490

Effectiveness

How Methylphenidate Affects Patients

Methylphenidate is a combination of two different isomers (d- and l-). The d-isomer is the active part of the drug, and binds to dopamine-rich areas of the brain, especially in the prefrontal cortex. This area is thought to be important in attention-deficit / hyperactivity disorder (ADHD). In animal studies, this drug has been shown to increase movement activity and cause repetitive behaviors.

How Methylphenidate works in the body

Methylphenidate helps people with ADHD by increasing the activity of two neurotransmitters, norepinephrine and dopamine, in the brain. Low doses of methylphenidate work to reduce impulsivity and improve cognitive functions like attention and memory. It also has an effect on alpha-1 adrenergic receptors, which helps with sustained attention. People with ADHD may have genetic abnormalities that affect the dopamine transporter gene, D4 receptor gene, and D2 receptor gene. Methylphenidate can help to overcome these genetic issues by increasing dopamine activity in the brain.

When to interrupt dosage

The amount of Methylphenidate is reliant upon the diagnosed situation. The dosage quantity may differ depending upon the technique of delivery featured in the table beneath.

Condition

Dosage

Administration

Attention Deficit Hyperactivity Disorder

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Narcolepsy

20.0 mg, , 30.0 mg, 40.0 mg, 10.0 mg, 60.0 mg, 27.0 mg, 36.0 mg, 54.0 mg, 50.0 mg, 5.0 mg, 2.5 mg, 5.0 mg/mL, 10.0 mg/mL, 18.0 mg, 80.0 mg, 15.0 mg, 10.0 mg/hour, 20.0 mg/hour, 15.0 mg/hour, 30.0 mg/hour, 30.0 mg/mL, 6.0 mg/mL, 7.5 mg/mL, 9.0 mg/mL, 8.6 mg, 25.9 mg, 17.3 mg, 1.0 mg/mL, 2.0 mg/mL, 25.0 mg, 35.0 mg, 55.0 mg, 70.0 mg, 85.0 mg, 100.0 mg, 45.0 mg, 72.0 mg, 63.0 mg

, Oral, Capsule, extended release, Capsule, extended release - Oral, Tablet - Oral, Capsule, Capsule - Oral, Tablet, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, chewable - Oral, Solution, Solution - Oral, Tablet, chewable, Tablet, extended release, Tablet, extended release - Oral, Transdermal, Patch - Transdermal, Patch, Suspension, extended release - Oral, Suspension, extended release, Tablet, Chewable, Extended Release, Tablet, Chewable, Extended Release - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral

Warnings

Methylphenidate Contraindications

Condition

Risk Level

Notes

advanced arteriosclerosis

Do Not Combine

Gilles de la Tourette syndrome

Do Not Combine

Thyrotoxicosis

Do Not Combine

Pulse Frequency

Do Not Combine

Open-angle glaucoma

Do Not Combine

Hypertensive disease

Do Not Combine

Pulse Frequency

Do Not Combine

Tension-Type Headache

Do Not Combine

Generalized Anxiety Disorder

Do Not Combine

symptomatic cardiovascular disease

Do Not Combine

Tourette Syndrome

Do Not Combine

Pheochromocytoma

Do Not Combine

Tics

Do Not Combine

Agitation

Do Not Combine

There are 20 known major drug interactions with Methylphenidate.

Common Methylphenidate Drug Interactions

Drug Name

Risk Level

Description

Desflurane

Major

Methylphenidate may increase the hypertensive activities of Desflurane.

Diethyl ether

Major

Methylphenidate may increase the hypertensive activities of Diethyl ether.

Enflurane

Major

Methylphenidate may increase the hypertensive activities of Enflurane.

Halothane

Major

Methylphenidate may increase the hypertensive activities of Halothane.

Isoflurane

Major

Methylphenidate may increase the hypertensive activities of Isoflurane.

Methylphenidate Toxicity & Overdose Risk

Overdosing on morphine can cause vomiting, restlessness, tremors, overactive reflexes, muscle spasms, seizures (sometimes followed by a coma), feeling happy and excited, confusion, seeing or hearing things that aren't real, delirium, sweating, redness of the face, headaches, high body temperature, rapid heartbeat, heart rhythm problems, high blood pressure, wide pupils, and dryness of the mouth. The lowest toxic dose for mice is 190mg/kg when given orally.

image of a doctor in a lab doing drug, clinical research

Methylphenidate Novel Uses: Which Conditions Have a Clinical Trial Featuring Methylphenidate?

84 active studies are presently assessing the potential of Methylphenidate to provide relief for Attention Deficit Hyperactivity Disorder.

Condition

Clinical Trials

Trial Phases

Attention Deficit Hyperactivity Disorder

61 Actively Recruiting

Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2

Narcolepsy

2 Actively Recruiting

Not Applicable, Phase 1

Methylphenidate Reviews: What are patients saying about Methylphenidate?

5

Patient Review

9/8/2015

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I've been using these patches for eight years now and they're still the most effective treatment I've found. It's really convenient not having to remember pills, and it doesn't screw with my diet the way some other medications can.

5

Patient Review

4/8/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I have severe ADHD and this medicine makes me feel more normal than with out it. I also have depression and it helps that as well.... I actuallt dont jave any sode effects either. Hope it continues to help me.

5

Patient Review

5/31/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I've only been giving my son this medication for a short time, but I'm already seeing such an amazing difference in his behavior and school performance. His teacher even contacted me to tell me how much progress he's made! I really hope that this continues to work well for him. The only side effects he's mentioned are feeling slightly dizzy and nauseous, but other than that he says he feels fine.

5

Patient Review

9/8/2015

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I've been using the datrayna patches for eight years now, and they're by far the most effective treatment I've tried. I love not having to worry about forgetting pills, and it doesn't screw with my diet nearly as much as other medications have in the past.

5

Patient Review

4/8/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This medication has been instrumental in managing my ADHD and depression. I haven't experienced any negative side effects, which is great.

5

Patient Review

5/31/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I've only been giving my son this medication for a short time, but I've already seen such an amazing and positive difference in his behavior at school. His teacher even contacted me to tell me how well he was doing! I'm hoping the effects continue, as this has really made a world of difference for him.

4.7

Patient Review

10/14/2021

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This drug is excellent for my ADHD and has helped me a lot. The only downside is that it makes me feel like a zombie, but the benefits outweigh the costs.

4.7

Patient Review

7/12/2021

Methylphenidate for Recurring Sleep Episodes During the Day

This medication allowed me to focus and complete my chores for the day.

4.7

Patient Review

10/14/2021

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This treatment is highly effective for my ADHD and has helped me a great deal. The only downside is that it makes me feel zombie-like; however, the benefits outweigh the costs.

4.7

Patient Review

7/12/2021

Methylphenidate for Recurring Sleep Episodes During the Day

I felt more productive and focused while using this medication.

4.3

Patient Review

5/27/2016

Methylphenidate for Recurring Sleep Episodes During the Day

I have a mild condition and this pill helps me with that as well as a few other disorders. It's non-addictive and the side effects are manageable. The only issue I have is sometimes I bite the inside of my mouth, but gum or hard candy takes care of that. Overall, it's been a big help in my day-to-day life.

4.3

Patient Review

4/14/2018

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I have taken Adderall or Concerta for most of my life and all of my adult life. I'm currently hospitalized with a stage 4 wound located directly above my anus. During this hospitalization, they lowered my Concerta from 54mg down to 27mg. Upon my insistence and request, it has been increased to 36mg. I feel that 54mg would be a much more effective treatment.

4.3

Patient Review

5/27/2016

Methylphenidate for Recurring Sleep Episodes During the Day

I have a mild condition and I found this pill to be really helpful in managing it. It's non-addictive and the side effects are manageable. The only downside is that I sometimes bite the inside of my mouth when I'm taking it, but that's an easy fix. Overall, this drug has made a big difference in my life.

4.3

Patient Review

4/14/2018

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I have taken Adderall or Concerta for most of my life and all of my adult life, ironically I'm currently hospitalized with a stage 4 wound located directly above my anus. During this hospitalization they lowered my Concerta from 54mg down to 27mg and upon my insistence and a request it has been increase to 36mg. I feel that 54mg would be a much more effective treatment; however, the medical professionals here disagree.

4

Patient Review

10/20/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I have found that this medication helps me to focus better on tasks. The side effects are not ideal, but manageable. For instance, I often yawn and my palms get sweaty; however, I don't feel tired. All things considered, I think this drug is working well for me.

4

Patient Review

10/20/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This medication helps me focus on tasks better. The side effects are not ideal, but manageable. For example, I often yawn and my palms get sweaty; however, the drug is otherwise effective.

4

Patient Review

1/18/2020

Methylphenidate for Cognitive Impairment following Traumatic Brain Injury

I may benefit from another brand name but I am afraid of what happens when I don't have it to think

4

Patient Review

1/18/2020

Methylphenidate for Cognitive Impairment following Traumatic Brain Injury

I may see even better results with a different brand, but the thought of not having this medication is scary.

3.7

Patient Review

1/14/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I unfortunately had to rush my daughter to the ER after just two days of taking this medication. She started having rapid heartbeats and blacking out. It was very scary for all of us.

3.7

Patient Review

3/30/2021

Methylphenidate for Depression

The benefits I've experienced from this medication - more energy, focus, and happiness - have been great. It's also helped with my depression, making me feel less empty and more on-track overall. The only downside is that it doesn't last very long (I have to take it 5 times per day) and there can be some rebound effects when I stop taking it.

3.7

Patient Review

1/14/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I had to rushes my daughter to the ER after only two days of taking this medication. She started having rapid heartbeats and blacking out. It was very scary for all of us.

3.7

Patient Review

3/30/2021

Methylphenidate for Depression

I find that this medicine helps me be more alert and happier. The only downside is the rebound effect, where I feel worse after the effects of the drug wear off. 50mg per day

3.3

Patient Review

6/18/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Terrible

3.3

Patient Review

6/18/2019

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This was a terrible experience.

3

Patient Review

3/17/2021

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This does help with focus problems, but it unfortunately also causes anxiety and suicidal thoughts as side effects.

3

Patient Review

3/17/2021

Methylphenidate for Attention Deficit Disorder with Hyperactivity

This drug helped me focus, but I experienced side effects like anxiety and suicidal thoughts.

2

Patient Review

10/24/2017

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Kremers' generic Concerta was, unfortunately, not the same as the original drug my son had been taking. He began having more severe behavior problems soon after switching, so we stopped giving it to him.

2

Patient Review

4/7/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Unfortunately, this medicine came with a whole host of unsavory side effects, like a rapid heart beat, sweating, and decreased appetite. It also made it hard to concentrate and focus. While it did alleviate my condition to some degree, the side effects were not worth it.

2

Patient Review

10/24/2017

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Kremers' generic Concerta was unfortunately not equivalent to the original for my son. He began having worse behavior problems after switching, so we had to go back to the old brand.

2

Patient Review

4/7/2016

Methylphenidate for Attention Deficit Disorder with Hyperactivity

I experienced a whole host of negative side effects when taking this medication, including but not limited to: rapid heart rate, sweating, decreased appetite, and muscle twitching. These outweighed any benefits I saw from taking the drug, so I would not recommend it to others.

1.3

Patient Review

9/29/2017

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Unfortunately, this medication had very harmful effects on my mental state. I became suicidal and ended up hurting the people around me, both mentally and physically.

1.3

Patient Review

9/29/2017

Methylphenidate for Attention Deficit Disorder with Hyperactivity

Unfortunately, this medication had some pretty severe side effects for me. It made me feel incredibly suicidal and I started lashing out at the people around me, both mentally and physically.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about methylphenidate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What will methylphenidate do to a normal person?

"Do not drive after taking methylphenidate until you know how the medicine affects you, as it may cause dizziness, drowsiness, or changes in vision. Methylphenidate may also cause serious heart or blood vessel problems, which are more likely in patients with a family history of heart disease."

Answered by AI

Is methylphenidate a serious drug?

"Methylphenidate should only be used as prescribed by a doctor to avoid any serious health problems, including heart and blood pressure problems that could potentially be fatal. This medication has a risk of being habit-forming, so it should be used with caution by people who have mental/mood disorders or a substance use disorder."

Answered by AI

Is methylphenidate the same as Adderall?

"Adderall is the brand name for a mix of two stimulants called amphetamine-dextroamphetamine. Ritalin is the brand name for a stimulant called methylphenidate."

Answered by AI

Is methylphenidate a stimulant?

"Heres a rundown of how these drugs work:

These drugs work by increasing levels of the neurotransmitters dopamine and norepinephrine in the brain. This can help to improve focus, concentration, and task completion.

Stimulant medications that increase levels of dopamine and norepinephrine in the brain are often prescribed to treat children, adolescents, or adults diagnosed with attention-deficit hyperactivity disorder (ADHD). These drugs can help improve focus, concentration, and task completion."

Answered by AI

Clinical Trials for Methylphenidate

Image of Seattle Children's Hospital in Seattle, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Seattle, WA

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Seattle Children's Hospital

Image of St. Jude Children's Research Hospital in Memphis, United States.

Methylphenidate for Sickle Cell Disease

8 - 17
All Sexes
Memphis, TN

The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not. Primary Objective: • Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits. Secondary Objective: • Evaluate neurobehavioral and safety outcomes following MPH treatment. Exploratory Objective: • Evaluate decision-making and determinants influencing methylphenidate utilization among parents.

Phase 1
Recruiting

St. Jude Children's Research Hospital

Andrew Heitzer, PhD

Have you considered Methylphenidate clinical trials?

We made a collection of clinical trials featuring Methylphenidate, we think they might fit your search criteria.
Go to Trials
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA

The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.

Waitlist Available
Has No Placebo

The University of Iowa

Image of UCSF Nancy Friend Pritzker Psychiatry Building in San Francisco, United States.

Trigeminal Nerve Stimulation for ADHD in Children with Autism

7 - 14
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if external trigeminal nerve stimulation (eTNS) works to treat ADHD symptoms in children on the autism spectrum (ASD). It will also learn about the efficacy and tolerability of the eTNS device. The main questions it aims to answer are: * Does eTNS reduce ADHD symptoms? * Does eTNS improve core and associated features of ASD? Participation spans 8-12 weeks and includes: * 4-5 in-person visits * 4 brief virtual check-ins * Nightly use of the eTNS device with a small sticky patch applied to child's forehead * Randomized assignment (those who start with the sham device may try the active device later)

Recruiting
Device

UCSF Nancy Friend Pritzker Psychiatry Building

Image of The University of Texas at Austin in Austin, United States.

Transcranial Photobiomodulation for ADHD

18 - 44
All Sexes
Austin, TX

The investigators have previously shown that non-invasive methods of brain stimulation such as the administration of transcranial infrared light to the prefrontal cortex (PFC) can result in improvements to cognition and emotion as well as brain oxygenation. This method is called transcranial photobiomodulation (tPBM). The investigators hypothesize that tPBM can improve cognition and brain oxygenation in adults with attention deficit hyperactivity disorder (ADHD). The investigators will investigate the effects of repeated tPBM sessions on cognitive functioning in adults with ADHD. Specifically, the investigators hypothesize that participants that receive tPBM will show improvements in response control, sustained attention, and working memory, as well as improvements in prefrontal hemodynamics and a reduction in ADHD symptoms.

Waitlist Available
Online Trial

The University of Texas at Austin

Have you considered Methylphenidate clinical trials?

We made a collection of clinical trials featuring Methylphenidate, we think they might fit your search criteria.
Go to Trials
Image of Louisiana State University in Baton Rouge, United States.

Virtual Reality for ADHD

18 - 25
All Sexes
Baton Rouge, LA

The goal of this larger parallel group randomized trial is to test the impact of a virtual reality program for improving the ability of emerging adults (age 18-25) with attention deficit hyperactivity disorder (ADHD) to stay focused while completing homework and studying. This study compares the impact of using a virtual reality headset to using a virtual reality headset while also receiving feedback about levels of focus to a control group. The main question is whether participants demonstrate significantly improved concentration while completing homework and studying in virtual reality and whether they enjoy and prefer working in a virtual reality environment. Concentration is measured both through participant report and also using keyboard and mouse click data to assess work productivity objectively.

Phase 4
Waitlist Available

Louisiana State University (+1 Sites)

Joshua M Langberg, PhD

Image of Duke University in Durham, United States.

Organizational Skills Training vs Mindfulness for ADHD

13 - 17
All Sexes
Durham, NC

This randomized control trial comparing Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) among adolescents with a pre-existing ADHD diagnosis presenting to the Duke ADHD Program. Both treatments are eight 90 minute sessions. The research component will involve a pre-treatment assessment and post-treatment assessment. Both assessments will involve adolescents and one caregiver to complete questionnaires over REDCap. Rating scales will include ADHD symptom severity (Conners 3: self and parent report), functional impairment (IRS: self and parent report), executive functioning (BRIEF-2: parent report), emotion dysregulation (DERS: self and parent report), trait mindfulness (FFMQ: self report), organizational skills (BRIEF-2: parent report), treatment satisfaction (self report and parent report) and credibility (self report and parent report). Post-treatment assessments for feasibility will include attendance (measured over the course of treatment) and homework completion rates on a scale of 1 to 5 in which 5 indicates higher homework completion. We will also assess acceptability via individual items on a Likert scale (self report): overall satisfaction, how much was learned about ADHD, usefulness of information learned, content relevance to individual experience, comprehension of strategies, confidence about using strategies, likelihood of using strategies, helpfulness to share with the group, benefits from hearing from other group members, willingness to recommend the same treatment to others, and whether or not treatment was beneficial.

Recruiting
Has No Placebo

Duke University

John Mitchell, PhD

Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment

Phase 1 & 2
Waitlist Available

Kennedy Krieger Institute

Alison E Pritchard, PhD

Image of Montana State University in Bozeman, United States.

Speech-Gesture Combinations for Autism

Any Age
All Sexes
Bozeman, MT

This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and/or minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \[cry\], can promote successful understanding of words like "cry". The overarching goal is to help families effectively utilize gestures to support communication with their children.

Recruiting
Has No Placebo

Montana State University

Have you considered Methylphenidate clinical trials?

We made a collection of clinical trials featuring Methylphenidate, we think they might fit your search criteria.
Go to Trials